UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

Oncotarget, 2018-03, Vol.9 (17), p.13796-13806

2018

Volltextzugriff (PDF)

A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analog

Journal of immunological methods, 2023-12, Vol.523, p.113575-113575, Article 113575

2023

Volltextzugriff (PDF)

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth

Clinical cancer research, 2014-12, Vol.20 (23), p.6059-6070

2014

Volltextzugriff (PDF)

Inhibition of Tumor Growth and Metastasis in Non―Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

Clinical cancer research, 2013-10, Vol.19 (20), p.5699-5710

2013

Volltextzugriff (PDF)

Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed : a phenotype partially reversed by selective estrogen receptor modulators

Cancer research (Chicago, Ill.), 2005-08, Vol.65 (15), p.6593-6600

2005

Volltextzugriff (PDF)

Abstract 528: Evaluation of single agent merestinib (LY2801653) or emibetuzumab (LY2875358) and the combination in a xenograft tumor model bearing MET exon 14 skipping

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.528-528

2017

Volltextzugriff (PDF)

Abstract 1823: Characterization of the anti-angiogenic properties of merestinib (LY2801653), an oncokinase inhibitor

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1823-1823

2017

Volltextzugriff (PDF)

Abstract 5590: Combination of an oncokinase inhibitor merestinib with anti-PD-L1 results in enhanced immune mediated antitumor activity in CT26 murine tumor model

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5590-5590

2017

Volltextzugriff (PDF)

Abstract 519: Antitumor activity of MET antibody emibetuzumab (LY2875358) in combination with EGFR inhibitors in erlotinib resistant (ER) xenograft mouse models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.519-519

2017

Volltextzugriff (PDF)

Abstract 2647: Merestinib (LY2801653), targeting several oncokinases including NTRK1/2/3, shows potent anti-tumor effect in colorectal cell line- and patient-derived xenograft (PDX) model bearing TPM3-NTRK1 fusion

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2647-2647

2016

Volltextzugriff (PDF)

CXCR4 expression and circulating tumor cell (CTC) counts evaluated as prognostic markers in extensive disease small cell lung cancer (ED-SCLC) patients (pts)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e18558-e18558

2015

Volltextzugriff (PDF)

Abstract 3042: LY2801653: An orally bioavailable MET kinase inhibitor with inhibitory activity against the oncoproteins ROS1 and MKNK1/2

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3042-3042

2013

Volltextzugriff (PDF)

Abstract 4403: Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4403-4403

2014

Volltextzugriff (PDF)

Abstract 1738: Assay development for detecting cMET expression in circulating tumor cells (CTC), a potential patient tailoring marker for evaluation of cMET inhibitors

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.1738-1738

2012

Volltextzugriff (PDF)

Abstract A47: Circulating tumor cell (CTC) assay development for detection of phosphohistone H3 (pHH3) as a clinical pharmacodynamic (PD) marker for LY2523355, an Eg5 kinesin inhibitor

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A47-A47

2011

Volltextzugriff (PDF)

Abstract 2087: Detection of KRAS mutations in circulating tumor cells (CTCs) and in formalin-fixed, paraffin-embedded (FFPE) tissue using castPCR method

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2087-2087

2012

Volltextzugriff (PDF)

Abstract 2339: Prevalence of MET expression, activating mutations of KRAS and IDH1/2, and ROS1 fusions in cholangiocarcinoma patient tumor samples

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2339-2339

2013

Volltextzugriff (PDF)

Abstract A49: Circulating tumor cell (CTC) assay development for detection of H2AX as a clinical pharmacodynamic (PD) marker for Chk1 kinase inhibitors

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A49-A49

2011

Volltextzugriff (PDF)

Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis

The lancet. Gastroenterology & hepatology, 2021-07, Vol.6 (7), p.547-558

2021

Volltextzugriff (PDF)

Akt Activation, but not Extracellular Signal–Regulated Kinase Activation, Is Required for SDF-1α/CXCR4–Mediated Migration of Epitheloid Carcinoma Cells

Molecular cancer research, 2005-04, Vol.3 (4), p.227-236

2005

Volltextzugriff (PDF)

Paediatric acute hepatitis of unknown aetiology: a national surveillance investigation in the USA during 2021 and 2022

The lancet child & adolescent health, 2023-11, Vol.7 (11), p.773-785

2023

Volltextzugriff (PDF)

Ursodeoxycholic Acid in Intrahepatic Cholestasis of Pregnancy: A Systematic Review and Individual Participant Data Meta-analysis

Obstetrical & gynecological survey, 2021-09, Vol.76 (9), p.521-523

2021

Volltextzugriff (PDF)

Achieving compliance with the International Health Regulations by overseas territories of the United Kingdom of Great Britain and Northern Ireland

Bulletin of the World Health Organization, 2014-11, Vol.92 (11), p.836-843

2014

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Aktive Filter

ThemaPharmacology & Pharmacy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(23)

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

A competitive ligand binding assay for detection of neutralizing antibodies against an insulin analog

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth

Inhibition of Tumor Growth and Metastasis in Non―Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed : a phenotype partially reversed by selective estrogen receptor modulators

Abstract 528: Evaluation of single agent merestinib (LY2801653) or emibetuzumab (LY2875358) and the combination in a xenograft tumor model bearing MET exon 14 skipping

Abstract 1823: Characterization of the anti-angiogenic properties of merestinib (LY2801653), an oncokinase inhibitor

Abstract 5590: Combination of an oncokinase inhibitor merestinib with anti-PD-L1 results in enhanced immune mediated antitumor activity in CT26 murine tumor model

Abstract 519: Antitumor activity of MET antibody emibetuzumab (LY2875358) in combination with EGFR inhibitors in erlotinib resistant (ER) xenograft mouse models

Abstract 2647: Merestinib (LY2801653), targeting several oncokinases including NTRK1/2/3, shows potent anti-tumor effect in colorectal cell line- and patient-derived xenograft (PDX) model bearing TPM3-NTRK1 fusion

CXCR4 expression and circulating tumor cell (CTC) counts evaluated as prognostic markers in extensive disease small cell lung cancer (ED-SCLC) patients (pts)

Abstract 3042: LY2801653: An orally bioavailable MET kinase inhibitor with inhibitory activity against the oncoproteins ROS1 and MKNK1/2

Abstract 4403: Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models

Abstract 1738: Assay development for detecting cMET expression in circulating tumor cells (CTC), a potential patient tailoring marker for evaluation of cMET inhibitors

Abstract A47: Circulating tumor cell (CTC) assay development for detection of phosphohistone H3 (pHH3) as a clinical pharmacodynamic (PD) marker for LY2523355, an Eg5 kinesin inhibitor

Abstract 2087: Detection of KRAS mutations in circulating tumor cells (CTCs) and in formalin-fixed, paraffin-embedded (FFPE) tissue using castPCR method

Abstract 2339: Prevalence of MET expression, activating mutations of KRAS and IDH1/2, and ROS1 fusions in cholangiocarcinoma patient tumor samples

Abstract A49: Circulating tumor cell (CTC) assay development for detection of H2AX as a clinical pharmacodynamic (PD) marker for Chk1 kinase inhibitors

Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis

Akt Activation, but not Extracellular Signal–Regulated Kinase Activation, Is Required for SDF-1α/CXCR4–Mediated Migration of Epitheloid Carcinoma Cells

Paediatric acute hepatitis of unknown aetiology: a national surveillance investigation in the USA during 2021 and 2022

Ursodeoxycholic Acid in Intrahepatic Cholestasis of Pregnancy: A Systematic Review and Individual Participant Data Meta-analysis

Achieving compliance with the International Health Regulations by overseas territories of the United Kingdom of Great Britain and Northern Ireland

Aktive Filter

Suchergebnisse filtern